Guidelines for preclinical animal research in ALS/MND: A consensus meeting. - Wikidata - awgldk - TriplyDB

Guidelines for preclinical animal research in ALS/MND: A consensus meeting.

Guidelines for preclinical animal research in ALS/MND: A consensus meeting.

http://www.wikidata.org/entity/Q37698628

about

Different human copper-zinc superoxide dismutase mutants, SOD1G93A and SOD1H46R, exert distinct harmful effects on gross phenotype in mice A call for transparent reporting to optimize the predictive value of preclinical research Neuroinflammation in motor neuron disease Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis Therapeutic neuroprotective agents for amyotrophic lateral sclerosis Issues related to development of antiepileptogenic therapies.Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials Anti-epileptogenic clinical trial designs in epilepsy: issues and options Tempol moderately extends survival in a hSOD1(G93A) ALS rat model by inhibiting neuronal cell loss, oxidative damage and levels of non-native hSOD1(G93A) forms The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments A novel acylaminoimidazole derivative, WN1316, alleviates disease progression via suppression of glial inflammation in ALS mouse model Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis.A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis.Epilepsy therapy development: technical and methodologic issues in studies with animal models Identification of B6SJL mSOD1(G93A) mouse subgroups with different disease progression rates.The impact of fraudulent and irreproducible data to the translational research crisis - solutions and implementation.Experimental Design and Data Analysis Issues Contribute to Inconsistent Results of C-Bouton Changes in Amyotrophic Lateral Sclerosis.T₂-weighted MRI detects presymptomatic pathology in the SOD1 mouse model of ALS.Optimised and rapid pre-clinical screening in the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS).Reduction in hSOD1 copy number significantly impacts ALS phenotype presentation in G37R (line 29) mice: implications for the assessment of putative therapeutic agents Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis Genetic biomarkers for ALS disease in transgenic SOD1(G93A) mice Early detection of motor dysfunction in the SOD1G93A mouse model of Amyotrophic Lateral Sclerosis (ALS) using home cage running wheels.Genetic rodent models of amyotrophic lateral sclerosis CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis Identification of human monoclonal antibodies specific for human SOD1 recognizing distinct epitopes and forms of SOD1.Astroglial inhibition of NF-κB does not ameliorate disease onset and progression in a mouse model for amyotrophic lateral sclerosis (ALS)Dexpramipexole is ineffective in two models of ALS related neurodegeneration.Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule.A mouse model of familial ALS has increased CNS levels of endogenous ubiquinol9/10 and does not benefit from exogenous administration of ubiquinol10 Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients.Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice Comparative study of behavioural tests in the SOD1G93A mouse model of amyotrophic lateral sclerosis.Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS.Risk of Bias in Reports of In Vivo Research: A Focus for Improvement.

P2860

Q21560962-16243E54-F642-454A-B776-B8FFB1B8F561 Q24289327-E19800AB-2684-4F2D-8654-370F8A1F81B9 Q26776339-4F31DD9B-3E84-4F7E-A70F-64C7800A3694 Q26777929-6E466218-5686-4631-A7A4-F40A8B1D94F9 Q27015029-9BCF9B42-0EB1-49E0-8665-B252A6CC6A05 Q27016115-C4863696-9D39-473E-AB17-F560A96ECCF8 Q27021917-7B32EDE9-3617-45B2-A6E7-95AA29EDAAA2 Q27027689-FCC9347E-5890-4B78-AFBF-CF8D6B81B74C Q27315986-3727BF2B-9FC6-459F-A42A-A711C3AC90D7 Q28255782-B873573C-4A3A-41AD-8149-077620FF8730 Q28476761-51C21C46-7D85-4655-A5B3-79E21CE5D5DD Q28534767-F2290569-E361-4523-BA7D-8A9F1C1D4839 Q28539406-E3EF7BF9-5E0C-4208-8499-790B6882FC6E Q28550359-3531F3DA-3A9C-41C0-B7B3-276C7EAD773B Q30277241-70DF73C6-2B27-4A7D-802E-1CC254A58798 Q30473769-3817DFAC-F9F6-47C7-9BAD-025FAC64ED3A Q30543230-9C5135E2-49D4-4865-952F-3BCE5ACE36DB Q30668718-F2D0EEEA-2824-4047-8EAE-A6287BFD133F Q31140087-66AD943C-AD31-4A85-A7E7-E26F8BF3D5EE Q31155328-4A640E97-3304-4E19-AEB7-AEB632C4CB7A Q33581148-F18E1011-33AE-4855-9D98-95CA7FCC0FB0 Q34005426-88233627-1762-4D5A-B984-3C77C3E3E98C Q34051858-C6E5E09C-C75B-4EF4-A1A7-BC57BB67850E Q34081777-0679EBE8-5A53-40DB-9921-54552785C53A Q34193281-F4990666-A806-42FA-8201-8B452BFB2BCF Q34276554-417152A2-3FB2-4AAF-9863-297A8692A70A Q34497123-165ED2CC-0949-49BA-8B7B-1C1804EB48D5 Q34556952-CC895B9C-09C0-495D-B895-7441A56EA679 Q34680962-056D6F2E-7767-44BE-8873-2F7EB97FBAFA Q34684165-E3DB9768-2C0B-4C20-973D-6122EB8BA293 Q34698706-66DF87E9-BFA5-4F97-9399-7318283433BC Q34744144-70A4998E-33B2-4937-A83D-ECF7EC733CE4 Q34769867-94579006-EECE-45D5-AC91-D18CCD43EE9D Q34920387-7F7838E0-2930-4B28-AC98-B649B8453AB6 Q35175041-0787EC3F-CC49-4887-9C85-ADE59D281643 Q35583176-9984F360-6556-4A87-B925-95C201466F42 Q35594377-EBAC9FA9-87B7-4321-B252-9F9C755D41E6 Q35595854-954C4558-9F57-4563-B596-650947E04E8B Q35750311-99D04C21-D52D-484F-9347-949D2AA79399 Q35804501-2C522037-4F29-4127-88F7-F9910699E83A

P2860

Guidelines for preclinical animal research in ALS/MND: A consensus meeting.

http://www.wikidata.org/entity/Q37698628

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Guidelines for preclinical animal research in ALS/MND: A consensus meeting.

@en

Guidelines for preclinical animal research in ALS/MND: A consensus meeting.

@nl

type

label

Guidelines for preclinical animal research in ALS/MND: A consensus meeting.

@en

Guidelines for preclinical animal research in ALS/MND: A consensus meeting.

@nl

prefLabel

Guidelines for preclinical animal research in ALS/MND: A consensus meeting.

@en

Guidelines for preclinical animal research in ALS/MND: A consensus meeting.

@nl

P1433

Q37698628-F4CDC4EB-6E0D-4012-831D-22A717286E88

P1476

Q37698628-0689CE27-329A-4995-9467-F5F82F6DC615

P2093

Q37698628-1B253484-5379-4C47-BB61-A1504ED82AD7

Q37698628-5010EF68-1E73-42F0-BD01-7FAB4905DB0D

Q37698628-5290B345-9FF7-46BE-8208-AA1599235A10

Q37698628-672AFF6E-9FD8-496E-99AF-A1790EE0CE80

Q37698628-94E70FA0-8EE0-43AB-93E7-DC697A70529B

Q37698628-C158EFE4-CA75-474F-ADC4-E6CB57F62530

Q37698628-E1FB5479-BBCF-40D4-AAFC-2277C0AC7342

Q37698628-E85997E5-8642-4913-950A-530B535AB22D

Q37698628-EE582EAC-06F3-4878-BCE7-16FC3F76F8D8

Q37698628-F0618325-BA80-40A1-B873-507FF48702F6

P2860

Q37698628-1480637A-B657-4C8B-96B9-A1657575E871

Q37698628-30433143-FB9B-476E-8DE3-3CCFA6DB7A5C

Q37698628-304938CB-939F-43A2-B748-6B90D4AC9631

Q37698628-325B0BC5-E5A1-4F70-8DD0-4C30A000C3A0

Q37698628-33F49499-CD04-496F-AAB2-83EDE82E2B64

Q37698628-397F9D05-C181-411E-BE56-8301AEB1BEF0

Q37698628-3F4D167C-61BF-4942-AFB2-11B1BD19BDC6

Q37698628-47E0F5E4-4FA7-4B16-AC2E-BCE8893D6D36

Q37698628-4CA8E308-9457-4F2C-983E-DB5EE8FEB5FF

Q37698628-56E38FD5-EC30-4D27-8494-323AE0A29322

P304

Q37698628-FDEF36C5-EAAE-4EB4-A29E-C8748D0D136B

P31

Q37698628-092322C1-EBD4-4586-BED5-AE68D8341C90

P356

Q37698628-943E63D9-7CE5-47AD-96E6-50D0E8D97135

P433

Q37698628-DF86E64C-6F3D-49D1-B07D-AD9253F095B0

P478

Q37698628-8017A872-96E3-406F-A6D0-39C33406DC70

P50

Q37698628-45510ECD-3D22-4A5A-99D3-F84CE169AAA9

Q37698628-478FF5B7-ADFC-47C1-A0D7-E1751F1C3D53

Q37698628-54160BA8-A24F-4D9D-AE7D-D2A592FC563B

Q37698628-766B9231-9322-4678-9ED8-FEC2BDA562F1

Q37698628-9E1E6A65-1AC6-4256-96E3-8F564FA6F1B2

Q37698628-B0F4152C-F6AC-4F01-A5F6-8F7939FA90B0

Q37698628-E1DED7A9-52D1-45F8-AB0A-A38D6AAC0EAF

P577

Q37698628-0A3B7F20-C405-4A15-BE71-764C2D38089D

P5875

Q37698628-B661A577-7BB3-43F5-869A-FE38A3A6489E

P698

Q37698628-52646245-3F12-46BA-A16F-022DC0B947F6

P921

Q37698628-920EBF53-3AC9-41E9-A8C1-E1D25B27D3CA

P356

17482960903545334

P1433

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

P1476

Guidelines for preclinical animal research in ALS/MND: A consensus meeting.

@en

P2093

Birgit Schwalenstöcker

http://www.w3.org/2001/XMLSchema#string

Caterina Bendotti

http://www.w3.org/2001/XMLSchema#string

Detlev Stiller

http://www.w3.org/2001/XMLSchema#string

Eran Blaugrund

http://www.w3.org/2001/XMLSchema#string

Fernando Vieira

http://www.w3.org/2001/XMLSchema#string

Heiko G Niessen

http://www.w3.org/2001/XMLSchema#string

Jean-Philippe Loeffler

http://www.w3.org/2001/XMLSchema#string

Linda Greensmith

http://www.w3.org/2001/XMLSchema#string

Markus Ruegg

http://www.w3.org/2001/XMLSchema#string

Richard Mead

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.

Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis

Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6

Design, power, and interpretation of studies in the standard murine model of ALS

TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis

Lithium delays progression of amyotrophic lateral sclerosis.

Lost in translation: treatment trials in the SOD1 mouse and in human ALS.

P304

38-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/17482960903545334

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Stephan von Hörsten

Leonard H van den Berg

Albert C Ludolph

Pierre-François Pradat

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41577219

http://www.w3.org/2001/XMLSchema#string

P698

20184514

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis